Home Blog

01

Oct2020

SAVE THE DATE: PDCI Hosting Webinar on PMPRB Final Guidelines

SAVE THE DATE - PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, will be hosting a FREE webinar session relating to the long anticipated final guidelines published by the Patented Medicine Prices Review Board (PMPRB). The webinar will take place ... Read More

14

Jan2020

PMPRB and “Zero-dollar” Sales

W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

22

Jan2018

PMPRB myth busting (I): The imaginary link between Canadian price controls and R&D expenditures

The myth perpetuated by government and academics – and echoed in the media – is that the Patented Medicine Prices Review Board’s (PMPRB’s) current price control regime was somehow structured to go easy on patented drug prices in exchange for significant R&D commitments.  The upshot being that since the R&D ... Read More

05

Dec2017

Health Canada releases proposed PMPRB Price Regulations – The Charge of the Price Brigade

The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers.  At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week.  Why ... Read More

08

Nov2017

National Pharmacare: No need for “Repeal & Replace” Canadian edition

The ongoing debate about repealing existing public and private drug programs and replacing them with a one-size-fits-all national pharmacare program returned to the headlines with the release of a wide-ranging report from the Parliamentary Budget Officer (PBO) which estimates the cost of a federally administered universal pharmacare plan. The PBO study ... Read More

12

Sep2017

Revealing Payments to Physicians: “Health Leaders” going down the wrong road with the PMPRB.

Canada’s “health leaders” sponsoring the Open Pharma campaign should have checked with the Patented Medicine Prices Review Board (PMPRB) before advocating their ill-conceived and impractical proposal to have the federal government amend the Patented Medicines Regulations to force drug manufacturers to disclose payments to physicians via the PMPRB. An ... Read More